Efficacy of Add-on Amantadine to clonidine on severity of opioid withdrawal symptoms.
Phase 3
Recruiting
- Conditions
- Severity of opioids withdrawal symptoms.Opioid dependence, uncomplicatedF11.20
- Registration Number
- IRCT20090801002266N15
- Lead Sponsor
- Esfahan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 86
Inclusion Criteria
Satisfaction to participate in the study
Having DSM-V criteria for drug dependence
Regular and daily consumption of opium and heroin orally, injected or smoked
Exclusion Criteria
The patient's unwillingness to continue cooperation
Occurrence of any medical or moral conflict with the continued presence of the patient in the study
Occurrence of physical and mental problems requires special interventions in the management of opioid withdrawal
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The effects of amantadine in controlling of opioids withdrawal symptoms. Timepoint: The severity of withdrawal symptoms (initial outcome) on the first day (24 hours after the last dose of the drug) as a baseline assessment and then on days 3, 7, 14 and 21. Method of measurement: SOWS scale.
- Secondary Outcome Measures
Name Time Method